William Blair Issues Positive Estimate for TNYA Earnings

Key Points

• William Blair has raised its Q3 2025 earnings estimate for Tenaya Therapeutics to ($0.15) per share, an improvement from the previous estimate of ($0.28).
• In its latest earnings report, Tenaya Therapeutics reported ($0.14) EPS, exceeding analysts' expectations of ($0.20).
• Over 90% of Tenaya Therapeutics' stock is owned by hedge funds and institutional investors, underscoring strong investor interest in the company.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Analysts at William Blair upped their Q3 2025 EPS estimates for Tenaya Therapeutics in a report issued on Wednesday, August 6th. William Blair analyst S. Corwin now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their prior estimate of ($0.28). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. William Blair also issued estimates for Tenaya Therapeutics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($0.73) EPS.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06.

Several other brokerages have also recently issued reports on TNYA. Chardan Capital reissued a "buy" rating and set a $9.00 target price on shares of Tenaya Therapeutics in a report on Thursday, August 7th. Wall Street Zen upgraded shares of Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Tenaya Therapeutics in a research report on Friday, April 25th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $6.25.

Tenaya Therapeutics Trading Up 0.6%

Shares of NASDAQ TNYA traded up $0.00 during midday trading on Monday, reaching $0.87. The company had a trading volume of 1,216,894 shares, compared to its average volume of 2,763,321. The business's 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.66. Tenaya Therapeutics has a 1 year low of $0.36 and a 1 year high of $4.01. The stock has a market cap of $141.14 million, a P/E ratio of -0.91 and a beta of 3.01.

Institutional Trading of Tenaya Therapeutics

Large investors have recently bought and sold shares of the business. DAFNA Capital Management LLC acquired a new stake in Tenaya Therapeutics during the 1st quarter worth $27,000. Woodline Partners LP purchased a new position in Tenaya Therapeutics during the fourth quarter worth about $28,000. Commerce Bank purchased a new position in Tenaya Therapeutics during the fourth quarter worth about $29,000. Mariner LLC purchased a new position in Tenaya Therapeutics during the fourth quarter worth about $30,000. Finally, Ground Swell Capital LLC purchased a new position in Tenaya Therapeutics during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 90.54% of the company's stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.